AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2021

Dec 7, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK: 0001439222
Period of Report: 2021-12-03

Reporting Person: Biller Jonathan (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-03	Common stock	M	5753	—	Acquired	16623	Direct
2021-12-03	Common stock	F	1823	$35.8781	Disposed	14800	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-03	Restricted stock units	$	M	5753	Disposed		Common stock (5753.0)	Direct

Footnotes

F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

F2: Includes 830 shares purchased through the Company's employee stock purchase plan.

F3: The restricted stock units were granted on December 3, 2019. Beginning on December 3, 2020, the shares underlying the restricted stock units will vest in three equal annual installments.